Treatment outcomes of bladder/prostate rhabdomyosarcoma (RMS) in multi- and single-institutional trials are reviewed. Remarkable strides have occurred in the treatment of this disease. Decreasing duration of chemotherapy, less cumulative doses of radiation therapy, and improving survival have been documented. A focus on bladder preservation has not adversely affected survival in most studies. Even if organ preservation is not possible, improvements in urinary diversion surgical technique still offer improved quality of life. The IRS III was a pivotal study in improving survival and quality of life. We recommend protocol enrollment whenever available. We also emphasize the use of magnetic resonance imaging and second look surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.pcan.4500652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of Genitourinary Rhabdomyosarcoma in Phase 3 clinical trials.
World J Urol
December 2024
Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 668, Rochester, NY, 14642, USA.
Purpose: Pediatric Rhabdomyosarcoma (RMS) is a morbid and often lethal condition characterized by a paucity of clinical data. Beyond a detailed risk categorization system, it is unclear if genitourinary (GU) sites (bladder/prostate, paratesticular, female organs) have outcomes distinct from non-GU sites. This study pools primary data from phase-3 clinical trials involving pediatric RMS to evaluate this question.
View Article and Find Full Text PDFEditorial Comment on "Pediatric Urologic Oncology Series - Bladder/Prostate Rhabdomyosarcoma".
Urology
November 2024
University of Colorado, Department of Surgery, Division of Urology and the Surgical Oncology Program at the Children's Hospital Colorado, Aurora, CO.
Successful treatment of rare case of rhabdomyosarcoma of urinary bladder in adult, experience from tertiary hospital. Case report.
Int J Surg Case Rep
October 2024
Department of Surgery, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Introduction And Importance: Rhabdomyosarcoma [RMS] is a malignant soft-tissue neoplasm characterized by skeletal muscle differentiation. It accounts for 7 % of childhood malignancies and is, by a wide margin, the most common sarcoma of childhood (Pappo, 1996). Approximately 20 % of cases of childhood rhabdomyosarcoma occur in the genitourinary tract (vagina, urinary bladder, prostate, paratestis, and uterus), and they are most commonly observed in the head and neck region.
View Article and Find Full Text PDFPediatric Urologic Oncology Series-Bladder/Prostate Rhabdomyosarcoma.
Urology
November 2024
Duke University, Department of Urology, Raleigh, NC.
Background: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).
Patients And Methods: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!